Background
Chimeric antigen receptor (CAR) T-cell therapy target receptor tyrosine kinase-like orphan receptor 1 (ROR1) is broadly expressed in hematologic and solid tumors, however clinically-characterized ROR1-CAR T cells with single chain variable …
Cis-regulatory elements and trans-acting factors coordinate to regulate T helper cell differentiation. Liu et al. characterize the histone modification and chromatin interaction dynamics in this process. The H3K4me1 landscape established by MLL4 in nai…
Intraepithelial mast cells (IEMCs) were first observed 105 years ago, yet their functions remain enigmatic. Yang et al. reveal that IEMCs are required for epithelial gasdermin C activation and IEMC-epithelium crosstalk constitutes a critical step in ty…
Science Immunology, Volume 9, Issue 94, April 2024.
Science Immunology, Volume 9, Issue 94, April 2024.
Science Immunology, Volume 9, Issue 94, April 2024.
Background
Despite the current therapeutic treatments including surgery, chemotherapy, radiotherapy and more recently immunotherapy, the mortality rate of lung cancer stays high. Regarding lung cancer, epigenetic modifications altering cell cycle, ang…
Background
Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway with an oral therapy could benefit pat…
Background
As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both with and without toxicity. …
Background
Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on the tumor immune microenvironment (TIME). Therefore, there is a cl…
